Buehlmann


Quantification of ACE activity in CSF


ACE high sensitive

Reliable and sensitive quantification of Angiotensin Converting Enzyme (ACE) activity in
Cerebrospinal fluid (CSF) is still a challenge.  BÜHLMANN provides the first commercial CE marked and non-radioactive tool, allowing reliable ACE determination in CSF.


 High sensitive Assay

The BÜHLMANN ACE high sensitive assay is designed to quantify reproducibly increased ACE activity in CSF samples from suspected and confirmed  neurosarcoidotic patients. ACE activity measurement in diluted serum samples is possible as well.

The assay shows a detection limit of 1 U/L and can be applied either on microtiter plates with a kinetic reader or on some clinical chemistry analyzers. The determined dynamic range goes up to 24 U/L. Results can be retrieved within about half an hour.

The standardization of the assay is based on the well established  BÜHLMANN ACE kinetic assay for serum testing (order code: KK-ACK).

The prinicple of the assay is based, as in the ACE kinetic assay, on the cleavage of the synthetic substrate FAPGG into an amino acid derivate and a dipeptide. The kinetic of this cleavage reaction is measured by recording the decreasing absorbance at 340 nm.

ACE high sensitive
Method

Enzymatic Assay (kinetic)
- on microtiter plates with kinetic reader
- Analyzers (Pentra, KoneLab, Cobas Mira)

Time to Result ~30 min
Sample Type CSF / Serum (1:5)
Sensitivity 1 U/L
Dynamic Range 1.5 - 24 U/L
Order Code KK-ACF   130 tests

CE
Downloads


Instruction for use* Technical product information
english             
PDF [200 KB] PDF [200 KB]

* Multilingual document [EN, DE, FR, IT, ES]

ACE – Angiotensin Converting Enzyme

ACE is a membrane-bound glycoprotein produced by epithelioid cells of granulomatous tissue and was first reported to be increased in CSF in patients with neurosarcoidosis in the mid-1980s by Schweisfurth et al. Elevated levels understandably occur with other granulomatous diseases (typically rare in neurologic practice) but reports also suggest increased levels in association with CNS tumors and infections such as meningitis.

Neurosarcoidosis

Sarcoidosis is a multisystem granulomatous disorder of unknown etiology and can be present in any organ system. Most commonly it occurs in lungs, followed by the eyes and integument. Nervous system involvement is present in approximately 5% of cases. Multiorgan involvement is a strong clue pointing to sarcoidosis, but the disease may be restricted to the nervous system. Diagnosis may be difficult, or at least delayed, because the clinical presentation and course of the disease is heterogeneous.
A valid, reproducible marker with reasonable sensitivity and specificity for sarcoidosis could influence the degree of pursuit of the diagnosis and likelihood of finding an appropriate biopsy target. A confident diagnosis of neurosarcoidosis requires histologie confirmation of involved nervous system tissue.

Contact

BÜHLMANN Laboratories AG
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch

Your local distributor
Order
About us
Job opportunities

News

The recently launched EntroGen BRAF (V600E/K/D) test, that can be run on your real-time PCR instrument, is now CE-IVD marked

The EntroGen BRAF (V600E/K/D) test is a very useful tool for the detection of important mutations found in melanoma, because it detects, beside the V600E  more

INFINITI KRAS-BRAF study from the Basel Institut of Pathology published in the Diagnostic Molecular Pathology journal.

New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at  more

Recent publications on BÜHLMANN calprotectin assays

Three very interesting new papers have been published recently. Manz et al. describes the quality and usefulness of the BÜHLMANN calprotectin ELISA in an  more

NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND

BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb  more

Get our RSS - Feed